Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Belantamab SC
Belantamab · 2 trials · 1 indication
VGPR+ is defined as the percentage of participants with a confirmed VGPR or better (i.e., VGPR, complete response, stringent complete response).
| Arm | Type | Description |
|---|---|---|
| Belantamab SC Dose level (DL)1 /IV DL1/SC DL 2 /SC DL1 | EXPERIMENTAL | Participants will receive Belantamab subcutaneous (SC) dose level 1 (DL1) +Recombinant Human Hyaluronidase PH20 (rHuPH20) in Period 1; followed by Belantamab intravenous (IV) DL1 in Period 2; followed by Belantamab SC DL2 + rHuPH20 in Period 3; further followed by Belantamab SC DL1 + rHuPH20 in Period 4. Dose level 1 is the lowest dose level. |
| Belantamab IV DL1 /SC DL1 /SC DL2 /SC DL1 | EXPERIMENTAL | Participants will receive Belantamab IV DL1 in Period 1; followed by Belantamab SC DL1 + rHuPH20 in Period 2; followed by Belantamab SC DL2 + rHuPH20 in Period 3; further followed by Belantamab SC DL1 + rHuPH20 in Period 4 of the study. Dose level 1 is the lowest dose level. |
| Part 1: Dose escalation and expansion of belantamab monotherapy | EXPERIMENTAL | Belantamab will be administered in participants with RRMM until progressive disease (PD) |
| Part 2: Belantamab and belantamab mafodotin (delivered as separate drugs) dose range finding | EXPERIMENTAL | Participants with RRMM will receive belantamab and belantamab mafodotin |
| Part 3: Belantamab +pomalidomide/dexamethasone in 2L+ RRMM | EXPERIMENTAL | Participants with RRMM will receive belantamab in combination with pomalidomide-dexamethasone backbone. |
| Part 1b: Optional belantamab mafodotin | EXPERIMENTAL | Participants enrolled in Part 1 and Part 2 will be dosed until PD after which they will have the option to receive treatment with single agent belantamab mafodotin. |
| Name | Type | Description |
|---|---|---|
| Belantamab SC | DRUG | Belantamab will be administered via SC route. |
| Belantamab IV | DRUG | Belantamab will be administered via IV route. |
| Recombinant Human Hyaluronidase PH20 (rHuPH20) | DRUG | rHuPH20 will be administered via SC route. |
| Standard of care | DRUG | Participants will receive standard of care: Lenalidomide and/or anti-CD38 mAb as maintenance therapy. |
| Belantamab | DRUG | Belantamab will be administered. |
| Belantamab mafodotin | DRUG | Belantamab mafodotin will be administered. |
| Pomalidomide | DRUG | Pomalidomide will be administered. |
| Dexamethasone | DRUG | Dexamethasone will be administered. |
Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Participants at the time of signing the Informed Consent Form (ICF) must be aged 18 years old or greater or are of the legal age of consent in the jurisdiction in which the stud...
Top 20 of 25 competitors
Belantamab is an investigational antibody being studied for the treatment of multiple myeloma. It is being evaluated as a monotherapy and in combination treatments. The drug is in Phase 1 clinical development and is not yet approved by regulatory authorities.
Belantamab is a monoclonal antibody, indicated by its -mab suffix. It is being studied for its activity against multiple myeloma, a cancer of plasma cells. The specific molecular target is not disclosed in the available clinical trial information.
Belantamab is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety and efficacy of the drug in patients with multiple myeloma.
Belantamab is currently in Phase 1 clinical development. There are two active Phase 1 trials, one recruiting participants and one not yet recruiting. No completed trials have been reported, and the drug remains investigational.
Belantamab is being studied in two Phase 1 trials. NCT05714839 is recruiting 123 participants to evaluate the drug as monotherapy and in combinations for multiple myeloma. NCT07742527 is a planned study of 22 participants comparing subcutaneous and intravenous formulations, though it has not yet started recruiting.
Yes, Belantamab SC is an alternative name for Belantamab. The SC designation refers to the subcutaneous formulation, which is being compared with the intravenous formulation in one of the ongoing clinical trials for multiple myeloma.